Corrigendum to “Novel benzimidazole derivatives as selective CB2 agonists” [Bioorg. Med. Chem. Lett. 18 (2008) 3695–3700]

Pagé, Daniel; Balaux, Elise; Boisvert, Luc; Liu, Ziping; Milburn, Claire; Tremblay, Maxime; Wei, Zhongyong; Woo, Simon; Luo, Xi; Cheng, Yun‐Xing; Yang, Hua; Srivastava, Sanjay K.; Zhou, Fei; Brown, W. V.; Tomaszewski, Mirosław J.; Walpole, Christopher; Hodzic, Leila; St-Onge, Stéphane; Payza, Kemal

doi:10.1016/j.bmcl.2008.07.104

Cited by 13 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… Simplified pharmacophore model (pharmacophores circled) of a prototypical competitive BChE inhibitor A and application of this model on a recently described dual‐acting compound with an indazole ether scaffold ( B ) and on a CB 2 R‐selective ligand described by AstraZeneca ( C ) …”

Section: Introductionmentioning

confidence: 99%

“…Our knowledge about the orientation of pharmacophores for BChE inhibitors led to the observation that the pharmacophore model also applies to: 1) the benzimidazole‐based CB 2 R agonist described by AstraZeneca (Figure ) that we had used as parent ligand in the preparation of bivalent CB 2 R ligands, and 2) the dual‐acting ligand described by González‐Naranjo et al. (Figure ) .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Aminobenzimidazoles and Structural Isomers as Templates for Dual‐Acting Butyrylcholinesterase Inhibitors and hCB₂R Ligands To Combat Neurodegenerative Disorders

et al. 2015

View full text Add to dashboard Cite

A pharmacophore model for butyrylcholinesterase (BChE) inhibitors was applied to a human cannabinoid subtype 2 receptor (hCB2 R) agonist and verified it as a first-generation lead for respective dual-acting compounds. The design, synthesis, and pharmacological evaluation of various derivatives led to the identification of aminobenzimidazoles as second-generation leads with micro- or sub-micromolar activities at both targets and excellent selectivity over hCB1 and AChE, respectively. Computational studies of the first- and second-generation lead structures by applying molecular dynamics (MD) on the active hCB2 R model, along with docking and MD on hBChE, has enabled an explanation of their binding profiles at the protein levels and opened the way for further optimization. Dual-acting compounds with "balanced" affinities and excellent selectivities could be obtained that represent leads for treatment of both cognitive and pathophysiological impairment occurring in neurodegenerative disorders.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Aminobenzimidazoles and Structural Isomers as Templates for Dual‐Acting Butyrylcholinesterase Inhibitors and hCB₂R Ligands To Combat Neurodegenerative Disorders

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Incorporating a benzimidazole‐based selective CB 2 R agonist ( 9 ) , we recently synthesized two series of bivalent ligands for CB 2 R ( 10 and 11 , Fig. ) with different spacers by attaching at the amide position or the N‐ alkyl position of the imidazole ring, respectively .…”

Section: Bivalent Ligandsmentioning

confidence: 99%

Rational Modification of the Biological Profile of GPCR Ligands through Combination with Other Biologically Active Moieties

Huang

Nimczick

Decker

2015

Archiv der Pharmazie

View full text Add to dashboard Cite

In recent years, G protein-coupled receptor (GPCR) ligands have not only been modified by conducting structure-activity relationship studies of leads and known ligands, but several new approaches have emerged in which GPCR ligands were connected or merged with other biologically active molecules. Identical or related ligands were combined to bivalent ones. Orthosteric ligands were combined with allosteric ligands, sometimes leading to dualsteric ones, and also chemical structures were merged to dual-acting or multifunctional compounds. In this article, we want to present some representative examples for these approaches at different GPCRs, showing the versatility of this approach, with a focus on our own work and references to related articles and reviews.

show abstract

“…The benzimidazole system has been focus of our attention owing to their affinity to CB 2 cannabinoid receptors 1,2,3 . However there are few reports of their CB 1 receptors affinity 4 .…”

Section: Introductionmentioning

confidence: 99%

Docking and Synthesis of a series of 1-(naphthalen-1- ylmethyl)-2-(pyridin-2-yl)-1H-benzo[d]imidazole derivatives designed as novel CB1 cannabinoid ligands.

Mella¹,

Lagos²,

Romero-Parra³

et al. 2013

Proceedings of the 14th Brazilian Meeting on Organic Synthesis Proceedings

View full text Add to dashboard Cite

Corrigendum to “Novel benzimidazole derivatives as selective CB2 agonists” [Bioorg. Med. Chem. Lett. 18 (2008) 3695–3700]

Cited by 13 publications

References 0 publications

Aminobenzimidazoles and Structural Isomers as Templates for Dual‐Acting Butyrylcholinesterase Inhibitors and hCB₂R Ligands To Combat Neurodegenerative Disorders

Aminobenzimidazoles and Structural Isomers as Templates for Dual‐Acting Butyrylcholinesterase Inhibitors and hCB₂R Ligands To Combat Neurodegenerative Disorders

Rational Modification of the Biological Profile of GPCR Ligands through Combination with Other Biologically Active Moieties

Docking and Synthesis of a series of 1-(naphthalen-1- ylmethyl)-2-(pyridin-2-yl)-1H-benzo[d]imidazole derivatives designed as novel CB1 cannabinoid ligands.

Contact Info

Product

Resources

About

Corrigendum to “Novel benzimidazole derivatives as selective CB2 agonists” [Bioorg. Med. Chem. Lett. 18 (2008) 3695–3700]

Cited by 13 publications

References 0 publications

Aminobenzimidazoles and Structural Isomers as Templates for Dual‐Acting Butyrylcholinesterase Inhibitors and hCB2R Ligands To Combat Neurodegenerative Disorders

Aminobenzimidazoles and Structural Isomers as Templates for Dual‐Acting Butyrylcholinesterase Inhibitors and hCB2R Ligands To Combat Neurodegenerative Disorders

Rational Modification of the Biological Profile of GPCR Ligands through Combination with Other Biologically Active Moieties

Docking and Synthesis of a series of 1-(naphthalen-1- ylmethyl)-2-(pyridin-2-yl)-1H-benzo[d]imidazole derivatives designed as novel CB1 cannabinoid ligands.

Contact Info

Product

Resources

About

Aminobenzimidazoles and Structural Isomers as Templates for Dual‐Acting Butyrylcholinesterase Inhibitors and hCB₂R Ligands To Combat Neurodegenerative Disorders

Aminobenzimidazoles and Structural Isomers as Templates for Dual‐Acting Butyrylcholinesterase Inhibitors and hCB₂R Ligands To Combat Neurodegenerative Disorders